




Polymer-based nanoparticles

for active and passive targeted drug delivery to cancer cells

Konstantin Shevchenko, PhD


- Polymer-based nanoparticles and strategies for drug targeting
- Passive targeting to cancer cells by doxorubicin-loaded MIL-101 (Fe) MOFs
- Active targeting by EGFR-targeted MIPs

Polymer-based nanoparticles





- Biocompatibility
- Blood circulation time
- Bioconjugation
- Drug loading
- Sustained release
- Intricate architecture

Cell surface markers, EPR effect and localised release



Not so enhanced EPR effect







Flash release (FLARE)

Higher chances for acute toxicity


Waste of drug due to the fast blood clearance

BUT

Better delivery and higher efficacy?





MIL-101 (Fe) as a prospective carrier



BET surface area >1000 m²/g

Degradation time in phosphate-rich media 44 ± 7 s


Particle degradation kinetics matches flash drug release




BET surface area >1000 m²/g

Degradation time in phosphate and protein rich media ~ 15 min


MIL-101 (Fe) doesn't add up to the formulation toxicity





The drug release occurs prior to the particle uptake




MIL-101 (Fe) MOFs accumulate in lungs and liver



Doxorubicin-loaded MIL-101 NPs are more beneficial therapeutic option for the treatment of lung metastasis melanoma model




Doxorubicin-loaded MIL-101 NPs decrease size and number of metastatic nodules




Doxorubicin-loaded MIL-101 NPs

decrease size and number of metastatic nodules




12.7-fold decrease in nodule number




Prevention of nodule growth

- FlaRE delivery strategy relies on the minutes-scale degradation of drug-loaded nanocarriers in the tumour-surrounding blood vessels.
- Therapeutic potential of the FlaRE delivery is demonstrated by the treatment of melanoma pulmonary metastases in mice using doxorubicin loaded MIL-101 NPs.
- Strategy expands the repertoire of potential drug carriers by redefining their advantageous properties to prioritise rapid drug release kinetics.

Molecularly imprinted polymers (MIPs)



MIPs – the swiss-knife particles




 - fluorescent label

 - drug molecule payload

- Drug release
- Cell targeting
- Epitope tagging





in one particle

EGFR-binding nanoMIPs




MIP-0	(CG)TKGKLQSGF	N/A (scrambled sequence)
MIP-1	(CG)KLFGTSGQK	extracellular
MIP-2	(CG)GMNYLEDR	intracellular (kinase domain edge)
MIP-3	(CG)GVLGSGAFGTVYK	intracellular (kinase domain centre)
MIP-4	(CG)NLQEILHGAVR	extracellular
MIP-5	(CG)MHLPSPTDSNFYR	intracellular
MIP-6	(CG)LTQLGTFEDHFLSLQR	extracellular (EGF binding domain)

nanoMIPs modulate EGFR phosphorylation in MDA-MB-468 cells




EGFR nanoMIP binding results in:



- nanoMIPs selectively modify EGFR phosphorylation
- nanoMIPs modulate interaction EGFR with its specific ligand
- nanoMIPs is a promising platform for targeted co-delivery of small molecules

Acknowledgments



Institute of Bioorganic Chemistry, Moscow

Prof Sergey Deyev

Dr Ivan Zelepukin

Olga Gryaznova

Sechenov University, Moscow

Prof Andrei Zvyagin

Dr Artur Volovetsky

Dr Andrey Ivanov

University of Leicester, UK

Prof Sergey Piletsky

Dr Stanislav Piletsky

Dr Larisa Lezhina

Institute of Cytology RAS, St. Petersburg

Prof Nickolai Barlev

Dr Ekaterina Baidyuk

